Skyla
Drug Women's Health
NDC 50419-422-01
General payments
$189,251
Research payments
$140,719
Through program year 2021, $189,251 in general payments and $140,719 in research payments were reported against Skyla (Women's Health).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | General | $26,313 | 1,308 |
| 2021 | Research | $9,645 | 1 |
| 2020 | General | $49,687 | 1,640 |
| 2020 | Research | $63,551 | 2 |
| 2019 | General | $113,251 | 4,117 |
| 2019 | Research | $67,523 | 2 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2021.
The top 5 of 27 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.
The top 5 of 35 states; each share is of general payments naming this product in 2021 where a state was reported.
Records
7,065 general · 5 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.